Insmed Incorporated (LON:0JAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 16.95B +28.7% |
| Revenue (ttm) | 620.66M +115.1% |
| Net Income | -896.46M |
| EPS | -4.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,067 |
| Open | 104.01 |
| Previous Close | 104.52 |
| Day's Range | 104.01 - 108.08 |
| 52-Week Range | 91.59 - 214.00 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib...
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Mizuho cuts Insmed target, sees buying opportunity after selloff
Mizuho lowered the firm’s price target on Insmed (INSM) to $192 from $202 and keeps an Outperform rating on the shares. The firm finds it “shocking” how quickly investor sentiment…
Insmed Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
BRINSUPRI’s launch is exceeding benchmarks, with strong physician engagement and a robust support program driving persistence. Expansion into comorbid populations and upcoming launches in Japan are expected to fuel further growth, while a diverse pipeline and prudent financial strategy position the company for sustained success.
Insmed stock price decline a ‘buying opportunity’, says Roth Capital
Roth Capital keeps a Buy rating and a $212 price target on Insmed (INSM). The 10% decline in the stock on Friday is a buying opportunity with a move driven…
Insmed price target lowered to $179 from $180 at JPMorgan
JPMorgan lowered the firm’s price target on Insmed (INSM) to $179 from $180 and keeps an Overweight rating on the shares. The firm attributes the recent selloff to the expectation…
Insmed price target lowered to $195 from $205 at RBC Capital
RBC Capital lowered the firm’s price target on Insmed (INSM) to $195 from $205 but keeps an Outperform rating on the shares. The stock has seen positive momentum, but the…
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed Transcript: RBC Capital Markets Global Healthcare Conference 2026
Strong quarterly growth and operational execution support a $1B+ revenue target, with high payer approval and patient retention. Market expansion is driven by education, new patient identification, and robust pipeline progress, including ARIKAYCE and TPIP.
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Insmed files automatic mixed securities shelf
17:07 EDT Insmed (INSM) files automatic mixed securities shelf
Insmed price target lowered to $185 from $205 at Truist
Truist lowered the firm’s price target on Insmed (INSM) to $185 from $205 and keeps a Buy rating on the shares. The firm updated its model following Q1 results, incorporating…
Insmed Transcript: AGM 2026
The meeting established a quorum and proceeded with the election of two directors, approval of executive compensation, and ratification of the auditor. All proposals passed with no shareholder questions submitted.
Insmed Transcript: Bank of America Global Healthcare Conference 2026
BRINSUPRI's launch is exceeding expectations with strong sales, high physician engagement, and expanding market size. Pipeline progress, especially with TPIP, and disciplined research investments position the company for sustained growth and future profitability.
Insmed earnings selloff a buying opportunity, says H.C. Wainwright
H.C. Wainwright views the post-earnings selloff in shares of Insmed (INSM) as a buying opportunity. The “core Brinsupri launch thesis remains intact,” the analyst tells investors in a research note.
Insmed price target lowered to $185 from $200 at Raymond James
Raymond James lowered the firm’s price target on Insmed (INSM) to $185 from $200 and keeps an Outperform rating on the shares.
Insmed price target lowered to $226 from $230 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Insmed (INSM) to $226 from $230 and keeps a Buy rating on the shares. The firm’s target cut is largely…
Insmed price target lowered to $160 from $177 at Wells Fargo
Wells Fargo lowered the firm’s price target on Insmed (INSM) to $160 from $177 and keeps an Overweight rating on the shares. The firm thinks shares were weak on concerns…
Insmed pullback a buying opportunity, says Roth Capital
The 20% share decline in Insmed (INSM) shares post print reflects investor concern about limited visibility into Brinsupri’s organic demand trajectory, prescribing trends, and payer durability rather ...
Insmed reports Q1 EPS (76c), consensus ($1.00)
Reports Q1 revenue $306.0M, consensus $300.8M. “In the first quarter of 2026, momentum across Insmed’s (INSM) commercial portfolio and pipeline continued to build,” said CEO Will Lewis. “The trajector...
Insmed Earnings Call Transcript: Q1 2026
BRINSUPRI delivered exceptional sequential growth and is on track for $1B+ in 2026 revenue, with strong payer access, high compliance, and expanding prescriber base. ARIKAYCE and TPIP also advanced, while robust cash reserves support continued execution and pipeline growth.
Insmed Quarterly report: Q1 2026
Insmed has published its Q1 2026 quarterly earnings report on May 7, 2026.
Insmed Slides: Q1 2026
Insmed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.